SCHEMBL26922913

SCHEMBL26922913

c1coc(-c2nc3ccccc3n2Cc2ccncc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 12/20 0.70
▸ KDM4E B2RXH2 6/20 0.70
▸ HSD17B10 Q99714 5/20 0.70
▸ TSHR P16473 4/20 0.70
▸ USP2 O75604 2/20 0.70
▸ HPGD P15428 6/20 0.65
▸ TP53 P04637 1/20 0.65
▸ KCNK13 Q9HB14 5/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ LMNA P02545 2/20 0.58
▸ PKM P14618 1/20 0.58
▸ POLB P06746 2/20 0.56
▸ NPC1 O15118 1/20 0.55
▸ GLA P06280 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ CASP1 P29466 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ CASP7 P55210 1/20 0.55
▸ MAPT P10636 3/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30611753 1.00 ALDH1A1 (0.70) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL28186980 0.83 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL15567922 0.83 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL28378126 0.82 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL30611719 0.81 KCNK13 (0.62) ALDH1A1KDM4EHSD17B10TSHRHPGD
SCHEMBL18906367 0.81 KCNK13 (0.62) ALDH1A1KDM4EHSD17B10TSHRHPGD
SCHEMBL15569551 0.78 CASR (0.73) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL28943968 0.77 ALDH1A1 (0.71) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL8944756 0.77 PPARG (0.61) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL29412068 0.76 ALDH1A1 (0.82) ALDH1A1KDM4EHPGDTP53KCNK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158385-A1 NOVEL COMPOUNDS Cerevance, Inc. 2024-05-16 — — US claimed
EP-4288433-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2023-12-13 — — EP claimed
WO-2022167819-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2022-08-11 — — WO claimed
US-20240158385-A1 NOVEL COMPOUNDS Cerevance, Inc. 2024-05-16 — — US disclosed
EP-4288433-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2023-12-13 — — EP disclosed
WO-2022167819-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2022-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158385-A1 NOVEL COMPOUNDS KCNK3, KCNA4, KCNK13 ALDH1A1 2143/4885KDM4E 851/4885HSD17B10 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback